In a phase 1 clinical trial using recombinant human IL-21 (rhIL-21) in a dose-escalation study with 43 patients (24 melanoma and 19 renal cell carcinoma patients), rhIL-21 was administered consecutively for 5 days for two full cycles. Here, IL21 is linked to melanoma.